- NuVasive Inc.
- Given Imaging Ltd.
- Fibrocell Science Inc.
- Cardinal Health Inc.
- Cardinal Health, Alaris Products
- Boston Scientific Corp.
- Advanced Bionics Corp.
- Fisher Scientific International Inc.
- Cytyc Corp.
- Immunicon Corp.
- Bruker Corp.
- Myriad Genetics Inc.
- Encore Pharmaceuticals Inc.
- Aclara BioSciences Inc.
- Monogram Biosciences Inc.
- SeraCare Life Sciences Inc.
- Pressure BioSciences Inc.
- BBI Diagnostics
- Genomics Collaborative Inc.
- Zentiva BV
- Cytokinetics Inc.
- UCB Group
- UCB SA
- UCB Celltech
- Novelion Therapeutics Inc.
- QLT USA Inc.
- Aventis SA
- GlaxoSmithKline PLC
- Pfizer Inc.
- Hoffmann-La Roche Inc.
- Takeda California Inc.
- Merck & Co. Inc.
- Vertex Pharmaceuticals Inc.
- NuVasive nets $70.4mm in IPO
- Given Imaging grosses $60mm from public offering
- Isolagen nets $57mm with FOPO
- Cardinal Health to acquire Alaris Medical for $2bn
- Boston Scientific buys Advanced Bionics for $740mm; amended
- Fisher Scientific sells $300mm of convertible notes
- Cytyc sells $220mm of convertible notes
- Immunicon nets $51.34mm with IPO
- Bruker BioSciences nets $14.5mm with 3mm-share FOPO
- Myriad Genetics closes $50.2mm follow-on public offering
- Myriad gets rights to Encore Pharmaceuticals' MPC-7869
- Aclara BioSciences merges with ViroLogic
- SeraCare acquires two Boston Biomedica divisions
- SeraCare acquires Genomics Collaborative for cash and stock
- Zentiva closes €84.8mm IPO
- Cytokinetics nets $95.9mm with IPO
- UCB buys Celltech for £1.53bn in cash
- QLT acquires Atrix Labs
- Sanofi-Synthélabo closes takeover of Aventis
- GlaxoSmithKline acquires Sanofi-Synthelabo's antithrombotics
- Pfizer to buy Sanofi's Campto if Aventis buyout happens
- Roche, Syrrx develop cancer, diabetes compounds
- Merck & Co. licenses rights to Vertex's cancer compound
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.